See more : QEM Limited (QEM.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Revvity, Inc. (RVTY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Revvity, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Zhejiang Bofay Electric Co.,Ltd. (001255.SZ) Income Statement Analysis – Financial Results
- Stelux Holdings International Limited (0084.HK) Income Statement Analysis – Financial Results
- Malayan Cement Berhad (3794.KL) Income Statement Analysis – Financial Results
- Oji Holdings Corporation (OJIPF) Income Statement Analysis – Financial Results
- Nikki Global Finance Limited (NIKKIGL.BO) Income Statement Analysis – Financial Results
Revvity, Inc. (RVTY)
About Revvity, Inc.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.75B | 3.31B | 5.07B | 3.78B | 2.88B | 2.78B | 2.26B | 2.12B | 2.26B | 2.24B | 2.17B | 2.12B | 1.92B | 1.70B | 1.81B | 1.94B | 1.79B | 1.55B | 1.47B | 1.69B | 1.54B | 1.50B | 1.33B | 1.70B | 1.36B | 1.41B | 1.46B | 1.43B | 1.42B | 1.33B | 2.70B | 2.79B | 2.69B | 2.47B | 1.65B | 1.41B | 1.24B | 1.15B | 1.16B |
| Cost of Revenue | 1.21B | 1.32B | 2.22B | 1.67B | 1.49B | 1.44B | 1.18B | 1.10B | 1.24B | 1.23B | 1.19B | 1.15B | 1.07B | 945.72M | 1.03B | 1.11B | 1.06B | 918.29M | 859.30M | 1.01B | 906.27M | 904.10M | 721.73M | 918.43M | 787.30M | 991.30M | 1.04B | 1.01B | 1.01B | 957.80M | 2.30B | 2.39B | 2.31B | 2.14B | 1.35B | 1.11B | 984.00M | 935.30M | 927.90M |
| Gross Profit | 1.54B | 1.99B | 2.85B | 2.11B | 1.40B | 1.34B | 1.07B | 1.01B | 1.02B | 1.00B | 976.97M | 963.21M | 850.58M | 758.63M | 779.79M | 830.11M | 724.74M | 628.07M | 614.54M | 680.55M | 628.95M | 600.88M | 608.33M | 776.84M | 575.80M | 416.60M | 420.70M | 419.50M | 407.00M | 374.80M | 393.20M | 401.50M | 382.00M | 333.50M | 303.80M | 292.00M | 251.90M | 209.80M | 227.20M |
| Gross Profit Ratio | 55.98% | 60.08% | 56.27% | 55.78% | 48.41% | 48.27% | 47.54% | 47.90% | 45.28% | 44.90% | 45.10% | 45.54% | 44.27% | 44.51% | 43.03% | 42.84% | 40.55% | 40.62% | 41.70% | 40.34% | 40.97% | 39.93% | 45.74% | 45.82% | 42.24% | 29.59% | 28.80% | 29.39% | 28.67% | 28.13% | 14.57% | 14.40% | 14.21% | 13.48% | 18.41% | 20.76% | 20.38% | 18.32% | 19.67% |
| Research & Development | 216.58M | 221.62M | 274.97M | 205.39M | 189.34M | 194.00M | 139.40M | 124.28M | 125.93M | 121.14M | 133.02M | 132.64M | 115.82M | 95.41M | 107.25M | 108.06M | 111.62M | 99.72M | 87.37M | 87.05M | 83.15M | 86.45M | 81.32M | 86.12M | 71.20M | 46.00M | 44.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.02B | 1.03B | 1.23B | 917.89M | 815.32M | 811.91M | 616.17M | 600.89M | 598.85M | 659.34M | 585.85M | 632.73M | 628.60M | 490.66M | 504.70M | 522.88M | 444.41M | 376.85M | 365.46M | 387.54M | 386.40M | 431.30M | 411.15M | 418.98M | 327.10M | 226.30M | 243.40M | 290.90M | 284.90M | 278.20M | 234.60M | 242.00M | 223.10M | 195.90M | 179.90M | 169.30M | 151.40M | 133.20M | 130.10M |
| Other Expenses | 0.00 | 25.26M | 36.41M | -23.52M | -27.69M | -13.21M | 33.59M | -3.73M | -4.80M | -5.54M | -14.84M | -2.92M | -3.88M | -2.14M | 0.00 | 0.00 | -15.35M | 1.74M | -1.50M | 28.89M | 25.67M | 23.11M | 0.00 | 87.72M | 66.10M | 50.40M | 44.60M | 40.90M | 39.40M | 36.80M | 37.80M | 36.30M | 33.70M | 29.90M | 25.50M | 24.60M | 21.20M | 16.40M | 15.10M |
| Operating Expenses | 1.24B | 1.25B | 1.50B | 1.12B | 1.00B | 1.01B | 755.57M | 725.16M | 724.78M | 780.48M | 718.87M | 765.37M | 744.42M | 586.07M | 611.95M | 630.95M | 540.69M | 478.31M | 451.33M | 503.48M | 495.22M | 540.87M | 492.46M | 592.81M | 464.40M | 322.70M | 332.90M | 331.80M | 324.30M | 315.00M | 272.40M | 278.30M | 256.80M | 225.80M | 205.40M | 193.90M | 172.60M | 149.60M | 145.20M |
| Cost & Expenses | 2.45B | 2.57B | 3.72B | 2.80B | 2.49B | 2.44B | 1.94B | 1.83B | 1.96B | 2.01B | 1.91B | 1.92B | 1.82B | 1.53B | 1.64B | 1.74B | 1.60B | 1.40B | 1.31B | 1.51B | 1.40B | 1.44B | 1.21B | 1.51B | 1.25B | 1.31B | 1.37B | 1.34B | 1.34B | 1.27B | 2.58B | 2.67B | 2.56B | 2.37B | 1.55B | 1.31B | 1.16B | 1.08B | 1.07B |
| Interest Income | 72.13M | 3.59M | 2.24M | 1.01M | 1.50M | 1.14M | 2.57M | 702.00K | 673.00K | 667.00K | 650.00K | 747.00K | 1.88M | 832.00K | 1.04M | 4.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 98.81M | 103.96M | 102.13M | 49.71M | 63.63M | 66.98M | 43.94M | 41.53M | 38.00M | 36.27M | 49.92M | 45.79M | 24.78M | 15.89M | 17.16M | 82.14M | 41.70M | 0.00 | 0.00 | 47.71M | 105.08M | 279.72M | 128.31M | 74.63M | 7.00M | 0.00 | 64.60M | 8.90M | 0.00 | 121.80M | 12.10M | 0.00 | 900.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 431.77M | 427.00M | 311.44M | 246.51M | 214.03M | 180.59M | 105.00M | 99.97M | 121.48M | 125.26M | 154.94M | 126.87M | 129.26M | 108.96M | 113.11M | 125.10M | 103.50M | 66.84M | 124.38M | 89.51M | 89.78M | 96.11M | 84.26M | 127.26M | 66.10M | 50.40M | 44.60M | 48.20M | 36.00M | 36.80M | 30.50M | 31.10M | 29.70M | 19.90M | 15.00M | 17.70M | 12.20M | 16.40M | 15.10M |
| EBITDA | 713.56M | 1.30B | 1.73B | 1.20B | 609.55M | 518.76M | 424.63M | 405.96M | 378.63M | 322.61M | 331.73M | 223.24M | 200.06M | 267.04M | 200.91M | 262.65M | 264.89M | 219.24M | 287.59M | 266.58M | 223.51M | 156.13M | 200.13M | 311.28M | 177.50M | 82.10M | 166.20M | 135.90M | 118.70M | 168.00M | 151.30M | 154.30M | 154.90M | 127.60M | 113.40M | 115.80M | 91.50M | 57.20M | 79.00M |
| EBITDA Ratio | 25.94% | 36.19% | 34.45% | 32.00% | 20.09% | 18.13% | 20.32% | 18.21% | 18.02% | 15.02% | 17.19% | 15.25% | 11.40% | 15.41% | 14.39% | 16.42% | 15.20% | 14.24% | 24.34% | 15.80% | 17.83% | 14.58% | 21.19% | 18.36% | 17.89% | 5.83% | 11.38% | 9.52% | 8.36% | 12.61% | 5.61% | 5.53% | 5.76% | 5.16% | 6.87% | 8.23% | 7.40% | 5.00% | 6.84% |
| Operating Income | 300.56M | 742.70M | 1.33B | 978.58M | 361.97M | 323.88M | 304.80M | 283.07M | 286.13M | 210.74M | 217.44M | 195.66M | 89.70M | 153.60M | 147.61M | 192.97M | 168.17M | 153.40M | 234.29M | 177.07M | 183.91M | 123.37M | 197.58M | 184.03M | 104.40M | 31.70M | 121.60M | 87.70M | 82.70M | 131.20M | 120.80M | 123.20M | 125.20M | 107.70M | 98.40M | 98.10M | 79.30M | 40.80M | 63.90M |
| Operating Income Ratio | 10.93% | 22.43% | 26.29% | 25.87% | 12.55% | 11.66% | 13.50% | 13.38% | 12.65% | 9.42% | 10.04% | 9.25% | 4.67% | 9.01% | 8.15% | 9.96% | 9.41% | 9.92% | 15.90% | 10.49% | 11.98% | 8.20% | 14.86% | 10.86% | 7.66% | 2.25% | 8.32% | 6.14% | 5.83% | 9.85% | 4.48% | 4.42% | 4.66% | 4.35% | 5.96% | 6.98% | 6.42% | 3.56% | 5.53% |
| Total Other Income/Expenses | -117.59M | -90.86M | -54.88M | 39.09M | -124.83M | -66.20M | 1.10M | -50.51M | -42.12M | 4.60M | -53.76M | -140.50M | -26.77M | -10.78M | -15.79M | -45.61M | -16.88M | -2.67M | -74.29M | -38.33M | -56.39M | -32.87M | -163.43M | -39.54M | -66.50M | 124.30M | -35.80M | -7.30M | 3.40M | -76.90M | 1.10M | -2.10M | -4.90M | -500.00K | 1.40M | -700.00K | 1.70M | 31.50M | 24.70M |
| Income Before Tax | 182.98M | 651.84M | 1.28B | 906.36M | 237.14M | 257.68M | 296.72M | 244.07M | 244.02M | 169.60M | 153.33M | 50.59M | 62.93M | 161.98M | 130.68M | 147.36M | 151.29M | 150.74M | 66.66M | 136.75M | 80.88M | -8.55M | 34.15M | 144.49M | 44.90M | 156.00M | 54.00M | 80.40M | 86.10M | -17.10M | 121.90M | 121.10M | 120.30M | 107.20M | 99.80M | 97.40M | 81.00M | 72.30M | 88.60M |
| Income Before Tax Ratio | 6.65% | 19.68% | 25.26% | 23.96% | 8.22% | 9.28% | 13.15% | 11.54% | 10.79% | 7.58% | 7.08% | 2.39% | 3.28% | 9.50% | 7.21% | 7.61% | 8.46% | 9.75% | 4.52% | 8.10% | 5.27% | -0.57% | 2.57% | 8.52% | 3.29% | 11.08% | 3.70% | 5.63% | 6.07% | -1.28% | 4.52% | 4.34% | 4.47% | 4.33% | 6.05% | 6.93% | 6.55% | 6.31% | 7.67% |
| Income Tax Expense | 3.47M | 129.16M | 347.60M | 178.27M | 9.39M | 20.21M | 139.83M | 28.36M | 31.33M | 8.44M | -12.19M | -17.85M | 62.75M | 26.06M | 37.93M | 21.22M | 17.46M | 32.41M | 128.00K | 38.50M | 25.87M | -4.42M | 34.77M | 58.42M | 16.50M | 54.00M | 23.40M | 25.90M | 31.80M | 15.00M | 42.30M | 33.30M | 39.10M | 33.20M | 29.90M | 28.70M | 25.50M | 27.40M | 32.90M |
| Net Income | 693.09M | 569.18M | 943.16M | 727.89M | 227.56M | 237.93M | 156.89M | 234.30M | 212.43M | 157.78M | 167.21M | 69.94M | 174.00K | 135.92M | 85.60M | 126.41M | 131.69M | 119.58M | 66.53M | 96.04M | 52.96M | -4.14M | -620.00K | 90.52M | 28.40M | 102.00M | 33.70M | 60.20M | 54.30M | -32.10M | 79.60M | 87.80M | 81.20M | 74.00M | 69.90M | 68.70M | 55.50M | 44.90M | 55.70M |
| Net Income Ratio | 25.20% | 17.19% | 18.61% | 19.24% | 7.89% | 8.56% | 6.95% | 11.08% | 9.39% | 7.05% | 7.72% | 3.31% | 0.01% | 7.98% | 4.72% | 6.52% | 7.37% | 7.73% | 4.51% | 5.69% | 3.45% | -0.27% | -0.05% | 5.34% | 2.08% | 7.24% | 2.31% | 4.22% | 3.83% | -2.41% | 2.95% | 3.15% | 3.02% | 2.99% | 4.24% | 4.89% | 4.49% | 3.92% | 4.82% |
| EPS | 5.56 | 4.51 | 8.12 | 6.53 | 2.05 | 2.15 | 1.43 | 2.14 | 1.89 | 1.40 | 1.49 | 0.61 | 0.00 | 1.16 | 0.74 | 1.07 | 1.11 | 0.96 | 0.51 | 0.75 | 0.42 | -0.03 | -0.01 | 0.92 | 0.31 | 1.13 | 0.37 | 0.64 | 0.53 | -0.29 | 0.71 | 0.78 | 0.73 | 0.65 | 0.60 | 0.57 | 0.50 | 0.42 | 0.52 |
| EPS Diluted | 5.55 | 4.50 | 8.08 | 6.49 | 2.04 | 2.13 | 1.42 | 2.12 | 1.87 | 1.39 | 1.47 | 0.61 | 0.00 | 1.15 | 0.73 | 1.07 | 1.09 | 0.95 | 0.51 | 0.74 | 0.41 | -0.03 | -0.01 | 0.89 | 0.31 | 1.11 | 0.37 | 0.64 | 0.51 | -0.29 | 0.71 | 0.78 | 0.73 | 0.65 | 0.60 | 0.57 | 0.50 | 0.42 | 0.52 |
| Weighted Avg Shares Out | 124.70M | 126.16M | 116.17M | 111.51M | 110.83M | 110.56M | 109.86M | 109.48M | 112.51M | 112.59M | 112.25M | 113.73M | 112.98M | 117.11M | 116.25M | 117.66M | 118.64M | 124.57M | 129.52M | 128.06M | 126.09M | 125.57M | 104.56M | 98.39M | 91.30M | 90.27M | 91.08M | 94.80M | 103.03M | 112.00M | 112.57M | 112.56M | 111.23M | 113.85M | 116.50M | 119.48M | 111.00M | 108.19M | 107.12M |
| Weighted Avg Shares Out (Dil) | 124.81M | 126.43M | 116.67M | 112.09M | 111.50M | 111.53M | 110.86M | 110.31M | 113.32M | 113.74M | 113.50M | 114.86M | 113.86M | 117.98M | 116.59M | 118.69M | 120.81M | 125.88M | 131.43M | 129.79M | 129.17M | 125.57M | 107.83M | 101.71M | 91.30M | 91.89M | 91.08M | 94.80M | 105.98M | 112.00M | 112.57M | 112.56M | 111.23M | 113.85M | 116.50M | 119.48M | 111.00M | 108.19M | 107.12M |
Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow
Revvity's (RVTY) latest partnership is likely to address the workflow-related challenges faced by labs and democratize genomic sequencing.
Revvity and Element Biosciences Announce Collaboration to Improve Next Generation Sequencing Research Workflow
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, today announced a collaboration to introduce workflow solutions that save time and effort required for genomic...
Revvity To Hold Earnings Call on Monday, October 30, 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2023 financial results prior to market open on Monday, October 30, 2023. The Company will host a conference call the same day at 8:00 a.m....
Revvity's (RVTY) New Launch to Widen Access to Editing Technology
Revvity's (RVTY) latest offering is likely to improve access to new-generation editing technology and bridge both preclinical and clinical discoveries with the same technology platform.
Revvity Expands Access to Base Editing Technology With Aim to Accelerate Discovery to Cure
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., (NYSE: RVTY) today unveils its groundbreaking Pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories. Base editing represents a pivotal advancement in CRISPR gene...
Revvity (RVTY) Launches Three New Preclinical Research Systems
Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.
Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries.
Revvity, Inc. (RVTY) Q2 2023 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q2 2023 Earnings Conference Call August 1, 2023 8:00 AM ET Company Participants Stephen Willoughby - Vice President of Investor Relations Prahlad Singh - President and Chief Executive Officer Maxwell Krakowiak - Senior Vice President and...
Revvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS View
Revvity's (RVTY) second-quarter results reflect the impact of lower COVID-related sales. Both earnings and sales outpace their respective consensus estimate.
Source: https://incomestatements.info
Category: Stock Reports